Lexicon Pharmaceuticals LXRX
NASDAQ LXRX
$1.59 +0.00 (+0.32%)
As of: Oct 21, 2026 · 11:41 AM EDT

Lexicon Pharmaceuticals (LXRX) Finished Goods (2023)

Updated

Lexicon Pharmaceuticals' Finished Goods was $172,000 in Q2 2023.

Analysis

Lexicon Pharmaceuticals (LXRX) Finished Goods (2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,130.22 Bn 1,098.81 Bn 19.71 Bn
2 Johnson & Johnson 613.62 Bn 532.15 Bn 17.26 Bn
3 AbbVie 501.46 Bn 474.57 Bn 12.70 Bn
4 Merck 366.84 Bn 321.22 Bn 12.21 Bn
5 Novartis Ag 297.85 Bn 261.84 Bn 11.24 Bn
6 Astrazeneca 261.66 Bn 235.34 Bn 12.86 Bn
7 Amgen 235.39 Bn 190.79 Bn 7.24 Bn
8 Gilead Sciences 190.66 Bn 164.86 Bn 6.22 Bn
9 Pfizer 169.57 Bn 116.22 Bn 10.94 Bn
10 Lexicon Pharmaceuticals 693.68 Mn 120.23 Mn 653,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 172,000.00
API Access

Lexicon Pharmaceuticals Finished Goods API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=finished-goods&ticker=LXRX&period=max&api_key=YOUR_API_KEY